Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term study of CB03-154 in focal epilepsy
NCT07238868Phase 2Recruiting
- Sponsor
- Zhimeng Biopharma
- Start
- Aug 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CB03-154 in focal epilepsy, sponsored by Zhimeng Biopharma. Started Aug 2025; status: recruiting.
02
Drugs
CB03-154
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT07238868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238868.